What is CUE's P/E ratio?

CUE BIOPHARMA (CUE) currently trades at a P/E ratio of 80.56.

CUE BIOPHARMA reports a Return on Equity (ROE) of -90.35%.

What is CUE's dividend yield?

CUE BIOPHARMA offers a dividend yield of 0.00%.

What is CUE's Quality Score?

Our AI rates CUE's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CUE?

Our AI Timing Score for CUE is 66 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CUE belong to?

CUE BIOPHARMA is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

CUE (NASDAQ) Stock Analysis | CUE BIOPHARMA

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

CUE AI Analysis Summary

Our AI summary for CUE: CUE BIOPHARMA (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 80.56, ROE of -90.35%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 66/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CUE

CUE BIOPHARMA

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 26.84

-3.56 (-11.71%) Day Change

Watchlist Portfolio Compare Chart

80.56

P/E

0.07

D/E

-90.4%

ROE

-63.2%

ROA

0.00%

Div Yield

-1.99

PEG

CUE BIOPHARMA
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 26.84 Price -3.56 (-11.71%) Day Change	NEWS SCORE: N/A

CUE, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROA is too relatively low compare to ROE
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	26.84
PBV / Sector	5.91 / 5.20
Earning Per Share	-4.10

PE / Sector	80.56 / 19.97
PEG or PE/Growth / Sector	-1.99 / 1.22
Average 1M Daily Value	5.60 M GREAT
Average 1W Daily Value	7.48 M

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-59.65 / 98.71
NPM Average (%) / Sector	-1,155.28 / -1,721.76
NPM Change Average (%) / Sector	-61.80 / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-63.23 / 27.02
ROA Average (%) / Sector	-78.63 / -368.17
ROA Change Average (%) / Sector	11.36 / 5,404.12 GOOD
ROE (%) / Sector	-90.35 / 3.47
ROE Average (%) / Sector	-128.19 / 6.51
ROE Change Average (%) / Sector	18.12 / 2,128.13 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:41
Symbol	CUE
Name	CUE BIOPHARMA
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	4.20 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	127.69 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 40 Guest Street, Boston, MA, United States, 02135

Phone: 617 949 2680

Website: https://www.cuebiopharma.com

Sector: Healthcare >> Biotechnology

Description: Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.